Trial Outcomes & Findings for I-scan for Adenoma Detection (NCT NCT02811419)

NCT ID: NCT02811419

Last Updated: 2019-05-01

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

740 participants

Primary outcome timeframe

12 months

Results posted on

2019-05-01

Participant Flow

Participant milestones

Participant milestones
Measure
Intervention (I-scan)
i-scan 1 (surface enhancement with contrast enhancement)
Control (HDWL)
HDWL (High definition white light)
Overall Study
STARTED
369
371
Overall Study
COMPLETED
357
358
Overall Study
NOT COMPLETED
12
13

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

I-scan for Adenoma Detection

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
I-scan
n=369 Participants
Inspection with i-scan surface enhancement i-scan: examination will be performed with i-scan digital enhancement
Standard High-definition White Light
n=371 Participants
Inspection with standard high-definition white light (usual care) standard high-definition white light: examination will be performed with high-definition white light
Total
n=740 Participants
Total of all reporting groups
Age, Continuous
61.4 years
STANDARD_DEVIATION 7.5 • n=5 Participants
60.8 years
STANDARD_DEVIATION 7.5 • n=7 Participants
61.1 years
STANDARD_DEVIATION 7.5 • n=5 Participants
Sex: Female, Male
Female
185 Participants
n=5 Participants
187 Participants
n=7 Participants
372 Participants
n=5 Participants
Sex: Female, Male
Male
184 Participants
n=5 Participants
184 Participants
n=7 Participants
368 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
369 Participants
n=5 Participants
371 Participants
n=7 Participants
740 Participants
n=5 Participants
Region of Enrollment
United States
369 participants
n=5 Participants
371 participants
n=7 Participants
740 participants
n=5 Participants
body mass index
27.0 kg/m^2
STANDARD_DEVIATION 5.7 • n=5 Participants
26.5 kg/m^2
STANDARD_DEVIATION 4.9 • n=7 Participants
26.7 kg/m^2
STANDARD_DEVIATION 5.2 • n=5 Participants

PRIMARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
Intervention (I-scan)
n=369 Participants
i-scan 1 (surface enhancement with contrast enhancement)
Control (HDWL)
n=371 Participants
HDWL (High definition white light)
Number of Participants With Conventional Adenoma and Sessile Serrated Adenoma/Polyp Detected
208 Participants
171 Participants

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
Intervention (I-scan)
n=369 Participants
i-scan 1 (surface enhancement with contrast enhancement)
Control (HDWL)
n=371 Participants
HDWL (High definition white light)
Number of Participants With Conventional Adenoma Detected
174 Participants
140 Participants

Adverse Events

Intervention (I-scan)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control (HDWL)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Trilokesh Kidambi

University of California San Francisco

Phone: 909-973-0629

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place